Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Ivantis, founded in 2007 and headquartered in Irvine, California, is a company dedicated to designing, developing, and commercializing innovative technologies for treating eye diseases. Their mission is to create effective solutions for ophthalmology specialists and the millions of people worldwide affected by debilitating eye conditions. Since its inception, Ivantis has raised a total of $136.3 million in funding, demonstrating significant investor interest in their work.
The company's focus on addressing critical needs in ophthalmology has positioned them as a notable player in the medical device industry. However, it's important to note that on November 8th, 2021, Ivantis was acquired by Alcon, a global leader in eye care. This acquisition has likely impacted any potential plans for an initial public offering (IPO) that Ivantis may have had.
Given the acquisition by Alcon, there is currently no public information or credible reports regarding Ivantis's IPO prospects. As a subsidiary of a larger public company, it's unlikely that Ivantis will pursue an independent IPO in the near future. Investors interested in gaining exposure to Ivantis's technology and market potential may want to consider exploring investment opportunities in its parent company, Alcon, which is already publicly traded.
We at Linqto always recommend that potential investors conduct thorough research and consult with financial advisors before making any investment decisions. The medical device and ophthalmology sectors continue to evolve, and staying informed about industry developments is crucial for those interested in this space.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Ivantis's IPO prospects remain uncertain, investors interested in the innovative medical device sector don't have to wait on the sidelines. At Linqto, we offer members access to interests in promising pre-IPO companies, including potential leaders in healthcare technology. Our platform allows you to diversify your portfolio with lower minimum investments in emerging industry pioneers like Ivantis, potentially benefiting from their growth before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
